With New Venebio Opioid Advisor Tool, PrescribeWellness Pharmacies Can Identify Patients at High Risk of a Prescription Opioid Overdose and Offer Potentially Life-Saving Interventions
PrescribeWellness, the cloud-based services company that inspires collaboration for better health, today announced that it has partnered with life sciences research consultancy Venebio Group to leverage the company’s new prescription opioid risk assessment tool, Venebio Opioid Advisor™ (VOA).
PrescribeWellness and Venebio are working together to fight a crisis that is ravaging the U.S.: opioid abuse is currently the leading cause of death in people under 50, in both urban and rural areas. With network reach of over 200 million lives, PrescribeWellness is uniquely positioned to arm the most accessible healthcare professionals in our communities—pharmacists—with VOA, the only validated tool able to predict the likelihood of a life-threatening opioid overdose from a prescription opioid with 90-percent accuracy.
PrescribeWellness’ pharmacy network includes more than 4,000 small towns across America; in many of those communities, pharmacists are the only available healthcare professionals, positioning them alone on the front lines. Equipping pharmacists with VOA will increase their ability to identify high-risk patients, prompting life-saving interventions. By empowering pharmacists, PrescribeWellness and Venebio are fighting the opioid epidemic at the point of attack.
“Our pharmacies, armed with Venebio Opioid Advisor, can save lives and help mitigate the ongoing opioid epidemic in our country,” said Al Babbington, CEO of PrescribeWellness. “According to the CDC, 46 people die every day in the U.S. from a prescription opioid overdose. Community pharmacists across the country are on the front lines of this issue while working hard to help their patients manage prescriptions. VOA will help them ‘go beyond the fill’ to keep their patients safe and healthy.”
“Pharmacists see opioid-using patients far more often than their physicians do, making them uniquely positioned to intervene and help prevent overdoses with these high-risk patients,” said Lenn Murrelle, MSPH, Ph.D., president and CEO of Venebio. “We are convinced VOA will help PrescribeWellness deliver better service to their customers while improving healthcare outcomes.”
Mindy Smith, Vice President of Pharmacy Practice Innovation at PrescribeWellness, added, “Community pharmacists are medication experts and the most accessible healthcare providers in the country. We are excited to work with Venebio to add VOA to our technology suite, which helps community pharmacists play a pivotal role in the fight against the opioid epidemic.”
PrescribeWellness pharmacies will use this predictive healthcare algorithm in conjunction with the core PrescribeWellness technology suite to deliver advanced opioid user education and medication therapy management.
PrescribeWellness inspires collaboration for better health across America by connecting patients to locally owned community pharmacies. Its proprietary cloud-based platform empowers pharmacists to provide more effective preventive healthcare services, which improve medication adherence, chronic disease management, transitions in care and population health. With data integration and behavioral science at the foundation, PrescribeWellness software solutions position the pharmacist at the center of community healthcare prevention. Inc. 5000 named PrescribeWellness one of America’s Fastest Growing Privately-Held Companies for the past two years. For more information, please visit www.prescribewellness.com.
About Venebio Group
Venebio is a research consultancy that provides cost-effective, custom solutions for complex life sciences problems. By integrating the expertise of a global network of scientists in a broad range of biomedical fields, Venebio delivers comprehensive project management and problem-solving in genetic and molecular epidemiology, pharmacoepidemiology and pharmacovigilance, personalized medicine, bioinformatics, biomarker discovery and epidemiologic literature reviews and analysis. Learn more at www.venebio.com and voa.venebio.com.